000
| 02527cam 2200409zi 4500 |
---|
001 | 9.916714 |
---|
003 | CaOODSP |
---|
005 | 20221130092217 |
---|
006 | m o d f |
---|
007 | cr cn||||||||| |
---|
008 | 221028t20222022onc o f000 0 eng d |
---|
020 | |a9780660460291 |
---|
040 | |aCaOODSP|beng|erda|cCaOODSP |
---|
043 | |an-cn--- |
---|
086 | 1 |aHP5-148/2022E-PDF |
---|
245 | 00|aSummary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 : |brecommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults. |
---|
246 | 10|aRecommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults |
---|
246 | 17|aSummary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 |
---|
264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |c2022. |
---|
264 | 4|c©2022 |
---|
300 | |a1 online resource (3 pages) |
---|
336 | |atext|btxt|2rdacontent |
---|
337 | |acomputer|bc|2rdamedia |
---|
338 | |aonline resource|bcr|2rdacarrier |
---|
500 | |aIssued also in French under title: Recommandations sur l'utilisation chez les adultes du vaccin de rappel à ARNm Spikevax bivalent BA.4/5 (50 mcg) de Moderna contre la COVID-19 : résumé des mises à jour du Comité consultatif national de l'immunisation (CCNI) du 3 novembre 2022. |
---|
500 | |aCover title. |
---|
500 | |a"Pub.: 220546." |
---|
520 | |a"On November 3, 2022, Health Canada authorized the use of the Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine as a booster dose in individuals 18 years of age and older"--Overview, page 3. |
---|
650 | 0|aCOVID-19 (Disease)|xVaccination|zCanada. |
---|
650 | 0|aCOVID-19 (Disease)|xVaccination|xGovernment policy|zCanada. |
---|
710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
---|
710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
---|
775 | 08|tRésumé des mises à jour du Comité consultatif national de l'immunisation (CCNI) du 3 novembre 2022 : |w(CaOODSP)9.916716 |
---|
856 | 40|qPDF|s824 KB|uhttps://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-148-2022-eng.pdf |
---|
856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/summary-national-advisory-committee-immunization-november-3-2022-recommendations-use-moderna-spikevax-bivalent-mrna-50-mcg-covid-19-booster-vaccine-adults.html |
---|